自述“青霉素过敏”的人大多数在正规评估后结果为阴性——为什么会出现这种情况？不经核实终身保留过敏标签会付出什么代价？
Most people reporting a “penicillin allergy” prove negative on formal evaluation — why does this happen, and what price is paid when the unverified label stays in the chart for life?
IgE介导的青霉素过敏依赖针对β内酰胺半抗原的特异性抗体，这种致敏随时间衰减，十年后多数患者已不复存在；许多儿童期病毒疹也被误记为药物过敏，标签一经写入便终生携带。未核实的过敏标签迫使改用广谱替代药，推高艰难梭菌感染、耐药选择与费用。经风险评估、皮试或口服激发试验可安全去除标签（去标记），让多数患者重新用上一线药物。
IgE-mediated penicillin allergy requires specific antibodies against beta-lactam haptens, but this sensitization wanes with time and has vanished in most patients a decade later; many childhood viral rashes are also misrecorded as drug reactions, yet once written down the label persists for life. Unverified labels push clinicians toward broader-spectrum alternatives, raising C. difficile infection, resistance selection and costs. Risk-stratified assessment, skin testing or direct oral challenge can safely remove the label (delabeling), restoring first-line therapy for the great majority.
难度 专业 · 适合 高中(15-18)
CC BY 4.0 · 已核验 · Verified 2026-11-02
来源 · Source
Solensky, R. 等《药物过敏：2022年实践参数更新》，《过敏与临床免疫学杂志》（Journal of Allergy and Clinical Immunology）150卷6期，2022年，DOI:10.1016/j.jaci.2022.08.028
Solensky, R. et al., “Drug Allergy: A 2022 Practice Parameter Update”, Journal of Allergy and Clinical Immunology, 150(6), 2022, DOI:10.1016/j.jaci.2022.08.028
独立核验依据 · Independent verification: 核验依据 1 EUROPEPMC 标识 36122788：Drug allergy: A 2022 practice para
#药物超敏反应 #青霉素 #特异性IgE #过敏标签去除
奥马珠单抗治疗慢性自发性荨麻疹的药理机制是什么？
What is the pharmacologic mechanism of omalizumab in chronic spontaneous urticaria?
奥马珠单抗是人源化抗IgE单抗，与游离IgE的Cε3区结合并加速其清除；血清游离IgE骤降后，肥大细胞与嗜碱粒细胞表面的高亲和力受体FcεRI表达下调，组胺等介质释放减少。慢性自发性荨麻疹主要由自身抗体持续激活皮肤肥大细胞，该药借此降低其反应性，被指南列为常规剂量抗组胺无效者的二线添加疗法。
Omalizumab is a humanized monoclonal antibody against IgE. By binding the Cε3 domain of free IgE and speeding its clearance, it abruptly lowers serum free IgE; high-affinity IgE receptors (FcεRI) on mast cells and basophils are then downregulated, and histamine release falls. Since chronic spontaneous urticaria is driven mainly by autoantibody activation of skin mast cells, omalizumab blunts this reactivity and serves as second-line add-on therapy when standard-dose antihistamines fail.
难度 专业 · 适合 高中(15-18)
CC BY 4.0 · 来源待核验 · Source pending review
来源 · Source
出处备注：著录含书名，但缺版次 / 出版社 / 年份中的一部分，需编辑补全后才能做独立比对。
Zuberbier T等，《荨麻疹定义、分类、诊断与治疗指南（EAACI/GA2LEN/EDF/WAO 2017修订版）》，Allergy期刊2018年第73卷第7期1393-1414页
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria: the 2017 revision. Allergy, 2018;73(7):1393-1414
#奥马珠单抗 #慢性荨麻疹 #IgE #肥大细胞
为什么第二代口服抗组胺药（如非索非那定、氯雷他定）比第一代（如苯海拉明）更少引起嗜睡？
Why do second-generation oral antihistamines such as fexofenadine and loratadine cause much less drowsiness than first-generation agents like diphenhydramine?
嗜睡源于药物进入中枢并阻断H1受体。第二代抗组胺药多是血脑屏障上P-糖蛋白外排转运体的底物，药物被主动排出脑外，因而选择性作用于外周H1受体，缓解瘙痒、喷嚏和流涕而不产生明显镇静；第一代药物脂溶性强且不受该外排限制，易入脑阻断中枢H1受体，导致嗜睡并损害注意力和驾驶能力。
Drowsiness appears when an antihistamine enters the brain and blocks central H1 receptors. Most second-generation agents are substrates of the P-glycoprotein efflux transporter at the blood-brain barrier, which pumps them back out, so they act selectively on peripheral H1 receptors to relieve itching, sneezing and runny nose with little sedation. First-generation drugs are lipophilic, escape this efflux, penetrate the brain easily, and thereby blunt alertness, attention and driving performance.
难度 进阶 · 适合 初中(12-15)
CC BY 4.0 · 来源待核验 · Source pending review
来源 · Source
出处备注：此条未指向带版次的可引用著作（通识性内容、机构文件或未展开的英文书名），本库不提供独立书目出处；如需精确引用，需由编辑补全具体篇目与版次。
Simons FER, Simons KJ. H1抗组胺药进展. 新英格兰医学杂志, 2004 (DOI:10.1056/NEJMra043134)
Simons FER, Simons KJ. Advances in H1-antihistamines. New England Journal of Medicine, 2004 (DOI:10.1056/NEJMra043134)
#抗组胺药 #血脑屏障 #P糖蛋白 #镇静作用